GlaxoSmithKline PLC is setting up a new company with Verily Life Sciences LLC (formerly Google Life Sciences) called Galvani Bioelectronics. Galvani, which will be 55% owned by GSK and 45% by Verily, will work to develop and commercialize bioelectronic medicines.
Moncef Slaoui (currently GSK's vaccines chief but the former head of R&D), will chair the board of the new company. A GSK spokesperson told Scrip that Slaoui's decision to leave GSK next year will not affect his position at Galvani